Healthcare resource utilization and costs for extended interval dosing of natalizumab in multiple sclerosis.

IF 2.3 Q3 CLINICAL NEUROLOGY

Neurodegenerative disease management Pub Date : 2022-06-01 DOI:10.2217/nmt-2021-0038

Marcello Moccia, Ilaria Loperto, Laura Santoni, Silvia Masera, Giuseppina Affinito, Antonio Carotenuto, Roberta Lanzillo, Maria Triassi, Vincenzo Brescia Morra, Raffaele Palladino

{"title":"Healthcare resource utilization and costs for extended interval dosing of natalizumab in multiple sclerosis.","authors":"Marcello Moccia, Ilaria Loperto, Laura Santoni, Silvia Masera, Giuseppina Affinito, Antonio Carotenuto, Roberta Lanzillo, Maria Triassi, Vincenzo Brescia Morra, Raffaele Palladino","doi":"10.2217/nmt-2021-0038","DOIUrl":null,"url":null,"abstract":"Aims: Natalizumab is approved as an infusion every 4 weeks (standard-interval dosing [SID]) in relapsing-remitting multiple sclerosis (MS). Extended-interval dosing (EID) reduces risk of progressive multifocal leukoencephalopathy (PML) compared with SID, but the impact on healthcare resources and costs remains unknown. Methods: In this population-based study, we included 208 natalizumab-treated MS patients who were classified into EID (≤15 infusions in the previous 18 months; n = 51; age = 33.7 ± 11.1 years; female = 72.5%) and SID (>15 infusions in the previous 18 months; n = 157; age = 36.5 ± 10.8 years; female = 68.1%) groups. Results: Natalizumab EID had fewer MS outpatient visits (p = 0.01) and related costs (p = 0.03), and lower natalizumab costs (p < 0.01) compared with SID, without changes in other healthcare resources and costs. Conclusion: Natalizumab EID is associated with reduced direct treatment costs, apparently without additional healthcare burden.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"12 3","pages":"109-116"},"PeriodicalIF":2.3000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurodegenerative disease management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/nmt-2021-0038","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 4

Abstract

Aims: Natalizumab is approved as an infusion every 4 weeks (standard-interval dosing [SID]) in relapsing-remitting multiple sclerosis (MS). Extended-interval dosing (EID) reduces risk of progressive multifocal leukoencephalopathy (PML) compared with SID, but the impact on healthcare resources and costs remains unknown. Methods: In this population-based study, we included 208 natalizumab-treated MS patients who were classified into EID (≤15 infusions in the previous 18 months; n = 51; age = 33.7 ± 11.1 years; female = 72.5%) and SID (>15 infusions in the previous 18 months; n = 157; age = 36.5 ± 10.8 years; female = 68.1%) groups. Results: Natalizumab EID had fewer MS outpatient visits (p = 0.01) and related costs (p = 0.03), and lower natalizumab costs (p < 0.01) compared with SID, without changes in other healthcare resources and costs. Conclusion: Natalizumab EID is associated with reduced direct treatment costs, apparently without additional healthcare burden.

查看原文本刊更多论文

在多发性硬化症中延长纳他珠单抗间隔给药的医疗资源利用和成本。

目的:Natalizumab被批准为每4周输注一次(标准间隔剂量[SID])治疗复发-缓解型多发性硬化症(MS)。与SID相比，延长间隔给药(EID)可降低进行性多灶性白质脑病(PML)的风险，但对医疗资源和成本的影响尚不清楚。方法:在这项基于人群的研究中，我们纳入了208名接受那他单抗治疗的MS患者，这些患者被分为EID(过去18个月内≤15次输注;n = 51;年龄= 33.7±11.1岁;女性= 72.5%)和SID(18个月内>15次输注);n = 157;年龄= 36.5±10.8岁;女性= 68.1%)组。结果:Natalizumab EID减少MS门诊就诊(p = 0.01)和相关费用(p = 0.03)，降低Natalizumab成本(p)。结论:Natalizumab EID与降低直接治疗费用相关，显然没有额外的医疗负担。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neurodegenerative disease management CLINICAL NEUROLOGY-

CiteScore

4.30

自引率

0.00%

发文量